This move is aimed at encouraging foreign pharmaceutical companies to establish manufacturing units in the US, thereby reducing dependency on imports. Analysts suggest that this decision could significantly impact countries like India, which export a substantial volume of generic drugs and pharmaceuticals to the US market. Companies that rely solely on overseas manufacturing may face increased costs, potentially affecting pricing and supply chains. The announcement has already sparked discussions among global pharma stakeholders about adjusting strategies to comply with the new tariff rules.

This policy signals a major shift in US trade and healthcare strategy.

The post Trump Announces 100% Tariff on Imported Pharma Products appeared first on India Podcast.

Experts believe this decision reflects the essential nature of generic medicines. Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, said Indian generics make healthcare in the US affordable and accessible. As the world’s largest producer of generics, India’s contribution to global health remains undeniable.

India supplies nearly 80% of global generic medicines and sends around 35% of its pharma exports to the US. According to India Ratings and Research (Ind-Ra), Indian generics help the US healthcare sector save billions while ensuring quality standards.

While other Indian industries face steep tariffs, the pharmaceutical sector continues to enjoy exemptions under the Section 232 review. This balance between affordability and accessibility ensures that Indian pharma remains a vital partner for US healthcare.

The post India’s Generic Drugs Exempt from US Tariffs Amid Trade Tensions appeared first on India Podcast.